Stomach cancer study using chemo plus immunotherapy plus targeted drug
Part of Cancer, Digestive system clinical trials.
This Phase 1/2 trial tests a combination treatment for advanced or metastatic stomach and food-pipe (gastroesophageal junction) cancer: a chemotherapy regimen (CapeOX) plus the immunotherapy drug sintilimab and the targeted drug bevacizumab. It aims to see how well this combination controls the cancer and how safely it can be given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction adenocarcinoma (including certain subtypes like signet ring or mucinous).
- Your cancer is unresectable, recurrent, or metastatic, and you’re expected to live more than 3 months.
- You are 18–70 years old, and you have at least one measurable tumor spot on scans.
- You have not had chemotherapy/immunotherapy/targeted therapy for your advanced disease recently (last major treatment should be finished at least 6 months ago if you had chemo/radiation).
- Your blood counts and organs are functioning enough (for example: hemoglobin, white cells, platelets, liver tests, kidney function, and clotting).
- You can share tumor tissue samples or recent pathology results for testing, and you can follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (XELOX), an immunotherapy drug (Sintilimab), and hyperbaric oxygen therapy for people with advanced or metastatic stomach or gastroesophageal junction cancer. The goal is to see if this triple therapy helps shrink or control the cancer better than current options.
This trial tests a combination of three drugs (lenvatinib, tislelizumab, and CapeOX chemotherapy) as the first treatment for advanced stomach or gastroesophageal junction cancer that is PD-L1 positive and has a low TMEscore. The goal is to see if this combination helps control the cancer better than standard treatments.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This trial compares a new drug combination (QLS31905 plus CAPOX chemo) with another combination (sintilimab plus CAPOX) as a first treatment for advanced stomach cancer. The goal is to see which approach works better.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
This trial tests a combination of immunotherapy (PD-1 inhibitor), a targeted drug (fruquintinib), and chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that is HER2-negative. It aims to see if this combination can shrink tumors and help people live longer.
Hear when a new Stomach Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.